Anti-inflammatory therapeutics for the treatment of atherosclerosis
Top Cited Papers
- 29 April 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 10 (5), 365-376
- https://doi.org/10.1038/nrd3444
Abstract
Current atherosclerosis therapies largely act by lowering lipid levels and although they are effective, patients are still at risk for major adverse cardiovascular events (MACE). It has recently emerged that inflammation has a major role in the development of MACE and this is not addressed by existing agents. Here, Charo and Taub discuss key anti-inflammatory targets and associated therapeutics that are now being developed to treat atherosclerosis. Atherosclerosis is the primary cause of heart disease and stroke and is thus the underlying pathology of the leading causes of death in the western world. Although risk can be reduced by lowering lipid levels, the equally important contribution of inflammation to the development of cardiovascular disease is not adequately addressed by existing therapies. Here, we summarize the evidence supporting a role for inflammation in the pathogenesis of atherosclerosis, discuss agents that are currently in the clinic and provide a perspective on the challenges faced in the development of drugs that target vascular inflammation.Keywords
This publication has 85 references indexed in Scilit:
- Part 9: Acute Coronary SyndromesCirculation, 2010
- Rationally Evolving MCP-1/CCL2 into a Decoy Protein with Potent Anti-inflammatory Activity in VivoJournal of Biological Chemistry, 2010
- Inflammation in Atherosclerosis From Pathophysiology to PracticeJournal of the American College of Cardiology, 2009
- Progressive Multifocal Leukoencephalopathy after Natalizumab MonotherapyThe New England Journal of Medicine, 2009
- Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2009
- LeukotrienesThe New England Journal of Medicine, 2007
- Role of N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency RoomClinical Chemistry, 2005
- Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary diseasePhysiological Genomics, 2005
- Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary EventsThe New England Journal of Medicine, 2001
- Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatmentNature Genetics, 1999